Cancer reports最新文献

{"title":"The Relationship Between Serum Levels of Thyroglobulin Antibody and the Risk of Recurrence in Patients With Differentiated Thyroid Cancer","authors":"Amirian Fatemeh,&nbsp;Yaghoubi Mohammad Ali,&nbsp;Mehrad-Majd Hassan,&nbsp;Mohebbi Masoud,&nbsp;Layegh Parvin,&nbsp;Vazifeh-Mostaan Leila,&nbsp;Dadgar Moghaddam Maliheh,&nbsp;Amirian Zahra,&nbsp;Taghavi Ghazaleh","doi":"10.1002/cnr2.70191","DOIUrl":"https://doi.org/10.1002/cnr2.70191","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Thyroid Autoantibodies (TgAbs) are associated with autoimmune thyroid disorders and are also used in thyroid cancer follow-up to monitor for recurrence of disease. This study aimed to explore the potential utility of TgAbs as a surrogate tumor marker and examine the relationship between fluctuations in TgAbs levels and disease recurrence in patients with Differentiated Thyroid Cancer (DTC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cohort study was conducted on a sample of 97 patients who underwent thyroidectomy for differentiated thyroid cancer (DTC) between the years 2017 and 2021. Following surgery (with or without lymph node dissection), levothyroxine therapy and 131 iodine were prescribed (as necessary). Regular laboratory evaluations were conducted, which involved measuring Tg and TgAb at 3 and 6 months postoperatively. Patients were classified based on recurrence rate and different levels of TgAb, and ROC analysis was applied. All data were analyzed with SPSS24, and a <i>p</i>-value &lt; 0.05 was considered statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>For low-risk patients, TgAb trends over time showed an increase at 6 months, while for high-risk patients, TgAb levels continuously rose starting from 3 months. Although TgAb levels above the functional sensitivity threshold did not predict recurrence overall, changes in TgAb levels at 6 months compared to 3 months after surgery were indicative of recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In the entire population, having TgAb levels higher than the functional sensitivity threshold had no risk of various relapses. However, changes in TgAb serum levels at 6 months after surgery, compared to 3 months after surgery, can serve as an indication of tumor recurrence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70191","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144140791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and Chemotherapeutic Efficacy in Extrahepatic Cholangiocarcinoma With Lung Metastases","authors":"Chao Zhang,&nbsp;Shun Tu,&nbsp;Yanting Liao,&nbsp;Yaqiang Shu,&nbsp;Muyu Fu,&nbsp;Jiayue Li,&nbsp;Xiaohua Lei","doi":"10.1002/cnr2.70236","DOIUrl":"https://doi.org/10.1002/cnr2.70236","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Studies on lung metastases from extrahepatic cholangiocarcinoma (ECC) are rare. This study aims to fill this gap by analyzing the influencing factors, prognosis, and chemotherapeutic efficacy of ECC lung metastases, and to provide insights for optimizing medical care for patients with ECC lung metastases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We retrieved data from the Surveillance, Epidemiology and End Results (SEER) database for patients with metastatic ECC (stage M1) from 2018 to 2021. The study analyzed these characteristics using descriptive statistics. To calculate Hazard Ratios (HR), multivariate COX regression analyses were performed. Overall survival (OS) was estimated using the Kaplan–Meier method, and the survival of patients between groups was compared using the log-rank test.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 762 people participated in the study, 50.4% of whom were men. At the time of diagnosis, 17.8% of patients had pulmonary metastases. 52.5% received chemotherapy. Multivariate COX analysis identified lung metastases as a significant risk factor for death from metastatic ECC (HR 1.64, CI 1.32–2.03, &lt;i&gt;p&lt;/i&gt; &lt; 0.001). Treatment with chemotherapy (HR 0.20, CI 0.17–0.25, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) and female sex (HR 0.80, CI 0.67–0.94, &lt;i&gt;p&lt;/i&gt; = 0.008) were associated with a better prognosis. Therefore, we further compared the prognosis and chemotherapy outcomes of male and female patients with ECC lung metastases. The median survival of male patients with and without lung metastases was 2 and 5 months, respectively (&lt;i&gt;p&lt;/i&gt; = 0.016), whereas there was no significant difference in female patients (&lt;i&gt;p&lt;/i&gt; = 0.19). Regardless of gender, patients with lung metastases had significantly worse OS even after receiving chemotherapy (&lt;i&gt;p&lt;/i&gt; = 0.0065 in the male group and &lt;i&gt;p&lt;/i&gt; = 0.0075 in the female group). Regardless of gender, patients with lung metastases who did not receive chemotherapy had significantly shorter overall survival than those who received chemotherapy. Not receiving chemotherapy vs. receiving chemotherapy (male: 1 month vs. 5 months, &lt;i&gt;p&lt;/i&gt; &lt; 0.0001; female: 2 months vs. 9 months, &lt;i&gt;p&lt;/i&gt; &lt; 0.0001).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Pulmonary metastasis is an important prognostic factor in ECC and is associated with poorer survival, especially in male patients. Therefore, preventive measures and effective control of lung metastases (e.g., chemotherapy), especially in male patients, may improve survival in patients with ECC.&lt;/p&gt;\u0000 ","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70236","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Network Analysis Decipher ZNF384-Related miR-20b-5p and miR-424-5p in Colon Adenocarcinoma","authors":"Bo Zhang,&nbsp;Yoshihisa Matsumoto","doi":"10.1002/cnr2.70233","DOIUrl":"https://doi.org/10.1002/cnr2.70233","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>ZNF384 is a C2H2-type zinc finger protein (ZNF) which is implicated in DNA double-strand break (DSB) repair through the classical non-homologous end-joining (cNHEJ) pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To clarify the regulatory mechanisms involving ZNF384 in colon adenocarcinoma (COAD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>First, we conducted a differential expression gene (DEG) analysis of mRNA and lncRNA using TCGA-COAD RNA-Seq data. We also identified ZNF384-related mRNAs through Pearson's correlation coefficient calculation and conducted weighted gene co-expression network analysis (WGCNA) for these genes, leading to the identification of a cluster of 331 genes with strongly positive correlation to tumor, 84 of which overlapped with DEGs. Gene functional analysis showed enrichment of genes in DNA repair, replication fork, and cell cycle checkpoint signaling pathways. Protein–protein interaction (PPI) network analysis of these 84 genes led to the identification of the top 20 key mRNAs. Then we employed three machine learning methods to refine our selection of candidate genes from these intersecting mRNAs. We constructed a competitive endogenous RNA (ceRNA) network and identified two significant intersecting miRNAs, miR-20b-5p and miR-424-5p, which have been shown to act as a tumor suppressor gene and an oncogene, respectively. Additionally, we found that KIF14 and KIF18B are regulated by these two miRNAs in this ceRNA network, particularly in DNA damage repair and cell cycle. Finally, validation using an external dataset from the GEO database confirmed their expression patterns.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The current study clarifies the mechanisms of how miR-20b-5p and miR-424-5p work in colon cancer and underscores their predictive capabilities in colon cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the Anti-Tumor Effects and Molecular Mechanisms of Hairyvein Agrimonia Herb in Gastric Cancer Through Network Pharmacology and Experimental Validation","authors":"Hequn He,&nbsp;Xiaohui Jin,&nbsp;Xiaoyun Ding,&nbsp;Haizhong Jiang,&nbsp;Xuguang Wang,&nbsp;Yi Chen,&nbsp;Jiyun Zhu","doi":"10.1002/cnr2.70169","DOIUrl":"https://doi.org/10.1002/cnr2.70169","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Stomach cancer has become one of the most common types of cancer, with its mortality rate ranking third in the world. Currently, the main treatments for gastric cancer are surgery, radiation therapy, and chemotherapy. Although current treatments can effectively prevent postoperative metastasis and recurrence of gastric cancer, they may also bring various adverse reactions in the gastrointestinal tract and side effects such as bone marrow suppression. Years of research have confirmed that traditional Chinese medicine treatment for gastric and other cancers has distinct characteristics and advantages. Combined treatment can increase the tumor inhibition rate, reduce the side effects of radiation and chemotherapy, improve patients' quality of life, and prolong the survival prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study explores the anti-tumor effect and specific molecular mechanism of Hairyvein Agrimonia Herb on gastric cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The combination of network pharmacology technology and various experimental techniques, including in vitro cell verification, was carried out throughout the whole study. The results show that five active components in the Hairyvein Agrimonia Herb can act on 160 carcinogenic targets in gastric cancer. String correlation analysis, Cytoscape network topology analysis, core target screening, protein molecule docking, immunohistochemical expression levels, and survival immune correlation analysis revealed that the carcinogenic genes JUN, HIF1A, and PTGS2 may be the primary drug targets for Hairyvein Agrimonia Herb in treating gastric cancer. The active component quercetin shows the best inhibitory effect on the docking of the PTGS2 protein. Furthermore, the prognostic models constructed by the carcinogenic genes JUN, HIF1A, and PTGS2 are significantly correlated with the survival time of gastric cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides a new ethical basis and research direction for understanding the mechanism of action of Hairyvein Agrimonia Herb in treating gastric cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144091644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymorphisms in the FTO Gene and Their Association With Cancer Risk: A Comprehensive Review and Meta-Analysis","authors":"Fengran Guo,&nbsp;Yilong Gao,&nbsp;Hu Wang,&nbsp;Pengfei Zhou,&nbsp;Yanping Zhang,&nbsp;Zhihai Teng,&nbsp;Yaxuan Wang,&nbsp;Zhenwei Han","doi":"10.1002/cnr2.70162","DOIUrl":"https://doi.org/10.1002/cnr2.70162","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This meta-analysis aimed to clarify the connection between six polymorphisms in the FTO gene and susceptibility to cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The relevant literature on the relationship between FTO variants and cancer susceptibility was comprehensively gathered from PubMed, Scopus, Embase, Medline, and Web of Science prior to May 20, 2024.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our analysis revealed that FTO rs9939609 had a certain correlation with an elevated cancer risk within the Asian demographic q vs. r (OR = 1.22, 95% CI = 1.07–1.39, <i>p</i> = 0.003); rq + qq vs. rr (OR = 1.18, 95% CI = 1.04–1.35, <i>p</i> = 0.011); qq vs. rr + rq (OR = 1.78, 95% CI = 1.39–2.27, <i>p</i> = 0.001). Additionally, FTO rs1477196 was linked to a higher risk of thyroid cancer qq vs. rr + rq (OR = 1.47, 95% CI = 1.13–1.91, <i>p</i> = 0.004) and remarkably relevant to an increased cancer susceptibility for Caucasians (q vs. r (OR = 1.29, 95% CI =1.06–1.57, <i>p</i> = 0.009); rq + qq vs. rr (OR = 1.37, 95% CI = 1.04–1.80, <i>p</i> = 0.024)). In the stratified analysis of rs8047395, the results indicated that rs8047395 had a certain correlation with cancer susceptibility for thyroid cancer q vs. r (OR = 1.23, 95% CI = 1.01–1.51, <i>p</i> = 0.041) and qq vs. rr + rq (OR = 1.53, 95% CI = 1.24–1.91, <i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>FTO rs9939609 showed a correlation with cancer risk among individuals of Asian descent. FTO rs1477196 was correlated with an increased risk for thyroid cancer and remarkably relevant to an increased cancer susceptibility for Caucasians. FTO rs8047395 was associated with the risk of thyroid cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70162","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144091645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humoral Immunity to Measles, Mumps, Rubella, Diphtheria, Tetanus and Pertussis After Cancer Treatment in Children","authors":"Susanna Sundell,&nbsp;Miia Laine,&nbsp;Liisa Järvelä,&nbsp;Ville Peltola,&nbsp;Tytti Vuorinen,&nbsp;Päivi Lähteenmäki,&nbsp;Linnea Schuez-Havupalo","doi":"10.1002/cnr2.70155","DOIUrl":"https://doi.org/10.1002/cnr2.70155","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Treatment for pediatric malignancies has distinct effects on the immune system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Our aim was to measure humoral immunity to measles, mumps and rubella (MMR), and diphtheria, tetanus and acellular pertussis (DTaP) vaccines after pediatric cancer treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>We assessed IgG titers of 52 children against the vaccine antigens post-treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After completed primary vaccination series for MMR and DTaP before treatment, post-treatment there was a considerable proportion of patients with below-reference titers against pertussis, diphtheria and tetanus, but only few subjects showed below-reference titers against measles, mumps and rubella. Our findings may have implications when considering re-vaccination policies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of Recurrence-Free Survival or Disease-Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials","authors":"Uchechukwu Love Anyaduba,&nbsp;Oluwatosin Qawiyy Orababa,&nbsp;Zion Faye,&nbsp;Nazia Rashid,&nbsp;Jason Shafrin,&nbsp;Gregory Reardon","doi":"10.1002/cnr2.70195","DOIUrl":"https://doi.org/10.1002/cnr2.70195","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer trials increasingly use surrogate endpoints, but it is unclear how well recurrence-free survival (RFS) or disease-free survival (DFS) specifically predict overall survival (OS) in resectable esophageal cancer (EC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic literature review identified trials with RFS/DFS and OS endpoints. A meta-analysis assessed RFS/DFS as surrogates for OS, estimating pooled hazard ratios (HRs) from trial HRs. Forest plots and heterogeneity tests showed effect sizes and pooled estimates. Unweighted linear regression and weighted sensitivity analysis estimated the correlation between OS and RFS/DFS, producing a regression plot.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 975 articles identified, 11 met the criteria. The pooled HR for OS and RFS/DFS was 0.90 and 0.87, respectively. The primary analysis showed a strong Pearson correlation between RFS/DFS and OS (<i>ρ</i> = 0.89, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Subject to known methodological limits, RFS/DFS was demonstrated to be a potentially suitable surrogate endpoint for OS in resectable EC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70195","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Interplay of Chronic Stress and Cancer: Pathophysiology and Implications for Integrated Care","authors":"Joyeeta Talukdar,&nbsp; Megha,&nbsp;Hemant Choudhary,&nbsp;Sushma Bhatnagar,&nbsp;Anuja Pandit,&nbsp;Ashwani Kumar Mishra,&nbsp;Subhradip Karmakar,&nbsp;Pratap Sharan","doi":"10.1002/cnr2.70143","DOIUrl":"https://doi.org/10.1002/cnr2.70143","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer-associated depression is a multifaceted condition that arises from the interplay of biological, psychological, and social factors in individuals diagnosed with cancer. Understanding this condition involves exploring how cancer and its treatments can precipitate depressive symptoms and the mechanisms behind this association. Chronic stress, inflammation, and immunological responses play a crucial role in the development of both cancer and depression. The objective of this review is to describe and synthesize information on the complex interactions between chronic stress, inflammation, immunological responses, and cancer development. Additionally, it aims to review existing evidence regarding mechanisms such as neurotransmitter imbalances, structural brain changes, and genetic predispositions as key contributors to depression in cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>A comprehensive literature search on Cancer-associated Depression was conducted in electronic databases, including APA PsycINFO, Medline, Google Scholar, Embase, PubMed, Scopus, and Web of Science. The research focused on understanding the potential relationship between stress-induced depression and cancer by examining neurochemical, anatomical, immunological, genetic, and psychological changes. The findings revealed a compilation of both quantitative and qualitative studies on depression in cancer patients. Evidence suggested a potential link between cancer-induced stress and depression, with increased levels of proinflammatory cytokines (such as IL-6) and dysregulation of neurotransmitters, including serotonin, contributing to the onset of depression. Furthermore, studies indicated that antidepressants, along with psychological interventions, were effective in managing depression among cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This narrative review provides insights into the importance of integrating oncology and mental health services to address the psychosocial needs of cancer patients. Future research should focus on the bidirectional interactions between stress and cancer, aiming to improve cancer care by incorporating mental health support. Addressing the mental health aspects of cancer treatment can significantly enhance patient outcomes and overall quality of life.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal Cancer Risk Loci: Prognostic Factors for Clinical Outcomes? A Systematic Review and Meta-Analysis","authors":"Chengmi Wu,&nbsp;Jingyi Zhou,&nbsp;Qian Wu,&nbsp;Shu Xu,&nbsp;Jie Jiang,&nbsp;Sha Li,&nbsp;Xuechen Chen","doi":"10.1002/cnr2.70230","DOIUrl":"https://doi.org/10.1002/cnr2.70230","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Several single nucleotide polymorphisms (SNPs) identified through genome-wide association studies (GWASs) on colorectal cancer (CRC) incidence are also shown as promising predictors of clinical outcomes in CRC patients. These genetic variants might help inform precision prognostic strategies by predicting disease progression, treatment response, and overall survival, thereby guiding more personalized treatment plans. However, conflicting evidence exists regarding their clinical relevance.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aim&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A systematic review and meta-analysis was performed to assess the potential of GWAS-identified SNPs in predicting CRC outcomes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods and Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We conducted a comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases up to 18 October 2024 for prospective studies that investigated the associations of CRC-related SNPs and polygenic risk scores (PRSs) built based on multiple SNPs with clinical outcomes. Quality of the included studies was assessed using the Newcastle–Ottawa Scale, and the heterogeneity was assessed by &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; index and Cochran's Q test. The final analysis included 22 studies with overall high quality and heterogeneity in several aspects (e.g., genetic models, ethnic background, and genetic signatures of CRC types). Among over 100 CRC risk-related loci, 12 SNPs were statistically associated with CRC clinical outcomes (mainly survival outcomes), which were replicated in multiple studies. Notably, rs9929218 and rs6983267, located in genes involved in processes of tumorigenesis, were linked to poor survival with hazard ratios (95% CIs) of 1.26 (1.12–1.42) under a recessive model and 1.33 (1.10–1.61) under an additive model, respectively, in the stratified analysis by genetic models. Besides, PRSs built based on survival-related SNPs were moderately associated with overall survival in CRC patients with hazard ratios exceeding 2.6 for each one-point increase in PRS.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Individual genetic variants and PRSs are predictive of CRC survival, and might serve as potential factors for risk stratification, which could help develop personalized treatment and surveillance strategies for CRC patients. However, the potential for false positives and the significant heterogeneity among studies that cannot be fully addressed in the current analysis due to limited data require a cautious interpretation of these findings. Large-scale studies are warranted to further explor","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Health-Promoting Lifestyle Behaviors on Gut Microbiota in Survivors of Hematological Cancer: A Scoping Review","authors":"Elham Samami,&nbsp;Angela Starkweather,&nbsp;Debra Lynch Kelly,&nbsp;Debra Lyon","doi":"10.1002/cnr2.70224","DOIUrl":"https://doi.org/10.1002/cnr2.70224","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>This scoping review aims to explore the relationship between health-promoting lifestyle behaviors and gut microbiota in survivors of hematological cancers, including leukemia, lymphoma, and multiple myeloma. Given the rising incidence of these malignancies and the associated treatment challenges, understanding how lifestyle factors influence gut health may provide insights into improving survivorship outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive search across multiple databases, including PubMed/Medline, CINAHL, and Scopus, following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR). The search strategy incorporated MeSH terms related to hematological cancers, health-promoting lifestyle behaviors, and gut microbiota. Inclusion criteria focused on primary research studies published in English that reported gut microbiota results in survivors of hematological cancers. A total of 1717 papers were initially identified, with 16 studies meeting the inclusion criteria after screening for relevance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review identified a significant association between health-promoting lifestyle behaviors, such as physical activity, nutrition, and stress management, and the composition and diversity of gut microbiota in cancer survivors. The findings suggest that engaging in these behaviors may enhance gut health, potentially mitigating treatment-related symptoms and improving overall quality of life. Notably, the studies highlighted the importance of tailored interventions that consider individual patient needs and preferences.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This scoping review underscores the critical role of health-promoting lifestyle behaviors in influencing gut microbiota among survivors of hematological cancers. Future research should focus on longitudinal studies to establish causal relationships and explore the mechanisms underlying these associations. By promoting healthy lifestyle choices, healthcare providers can enhance survivorship care and improve health outcomes for this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70224","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}